IceCure Medical (NASDAQ:ICCM – Free Report) had its target price reduced by HC Wainwright from $3.00 to $2.50 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for IceCure Medical’s FY2024 earnings at ($0.28) EPS, Q2 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.25) EPS.
IceCure Medical Price Performance
Shares of ICCM stock opened at $0.72 on Wednesday. IceCure Medical has a 12-month low of $0.52 and a 12-month high of $1.57. The firm has a market capitalization of $32.73 million, a price-to-earnings ratio of -2.17 and a beta of 0.57. The company has a quick ratio of 2.88, a current ratio of 3.39 and a debt-to-equity ratio of 0.03. The firm has a fifty day moving average of $0.72 and a 200-day moving average of $1.02.
IceCure Medical (NASDAQ:ICCM – Get Free Report) last announced its quarterly earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. IceCure Medical had a negative net margin of 444.30% and a negative return on equity of 101.66%. The company had revenue of $1.01 million during the quarter, compared to analyst estimates of $0.90 million. During the same quarter in the previous year, the business earned ($0.09) EPS. On average, equities research analysts forecast that IceCure Medical will post -0.28 earnings per share for the current year.
Hedge Funds Weigh In On IceCure Medical
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Read More
- Five stocks we like better than IceCure Medical
- Stock Market Upgrades: What Are They?
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Transportation Stocks Investing
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- Roth IRA Calculator: Calculate Your Potential Returns
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.